A randomized trial of tenecteplase versus alteplase for acute ischemic stroke.
By M. Parsons, N. Spratt, A. Bivard, B. Campbell, K. Chung, F. Miteff, Billy O’Brien, C. Bladin, P. McElduff, C. Allen and 4 more. New England Journal of Medicine, 2012
628 citations recorded by the source corpus.
Subfields: Cancer Research, Epidemiology, Molecular Biology
View Paper: https://www.semanticscholar.org/paper/9e4ac79d2f1612a718fd0f0683f22a36e2cfa571
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke (2021, methodology): “2) in order to limit heterogeneity in meta-analyses.(50,51) In the Phase IIB/III Trial of Tenecteplase in Acute Ischemic Stroke (TNK-S2B), 112 patients were randomised within three hours of stroke onset to tenecteplase 0.”